PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Vedolizumab - Immunotherapy related colitis

PAD Profile : Vedolizumab - Immunotherapy related colitis

Keywords :
Immune checkpoint inhibitors, monoclonal antibodies, leukocyte integrin
Brand Names Include :
Entyvio

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Important Information :
Only after steroids and infliximab (1st-line) have been ineffective
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve vedolizumab for the treatment of immunotherapy related colitis after steroids and infliximab (1st line) have been ineffective.

Vedolizumab will be assigned a RED traffic light status on the Prescribing Advisory Database (PAD)

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More